En Es

Industry News

Randox and Bosch Partner to Launch Molecular Diagnostics Platform

By Labmedica International staff writers
01 Mar 2018

Image: The Vivalytic all-in-one fully automated solution for molecular diagnostics (Photo courtesy of Randox Laboratories and Bosch Healthcare Solutions).Global healthcare diagnostics manufacturer Randox Laboratories (Crumlin, Northern Ireland, UK) has partnered with Bosch Healthcare Solutions GmbH (Waiblingen, Germany) to launch Vivalytic, an all-in-one fully automated solution for molecular diagnostics.

Randox develops, manufactures and markets diagnostic reagents and equipment for laboratory medicine. Its range of products includes Biochip Array Technology, clinical chemistry analyzers and reagents, quality control materials and schemes and an extensive life science portfolio. The company’s products and services are used in hospitals, clinical, research and molecular laboratories, food testing, forensic toxicology, life sciences, and veterinary laboratories.

Bosch Healthcare Solutions GmbH, a wholly owned subsidiary of Robert Bosch GmbH, develops products and services to improve people’s health and quality of life. The subsidiary’s solutions draw on the Bosch Group’s core competencies: sensors to collect data, software to evaluate that data, and services based on this data analysis.

Vivalytic combines the broadest range of test options and uses Randox-patented Biochip Array Technology, making it the easiest to use and most comprehensive multiplex PCR platform in the market. The device also supports single-plex and low-plex testing, simplifying the processes for otherwise complex laboratory test procedures. Depending upon the test application, Vivalytic delivers results from 30 minutes.

The first tests available on the Vivalytic are Randox’s panels for respiratory and sexually transmitted infections. The Respiratory Multiplex Array simultaneously detects 22 viral and bacterial pathogens, including Bordetella parapertussis, without the need for secondary or confirmatory testing to inform clinical treatment decisions. The STI array enables the detection of 10 viral, bacterial and protozoan STIs from a single urine or urogenital swab sample.

“This is transformational for patients and doctors; never before has there been this level of accessibility to such a wealth of molecular tests. Randox molecular assays continue to evolve, keeping precise diagnostics for targeted patient therapy at the centre. With Vivalytic, there’s no limit to the testing portfolio that can be made available on its universal platform, and importantly it delivers results quickly and accurately,” said Dr Peter FitzGerald, MD of Randox Laboratories.

“This is an ideal partnership for Randox, combining our expertise in molecular laboratory diagnostics with Bosch’s cutting-edge engineering. With antibiotic resistance one of the most pressing public health issues faced across the world today, we’re delighted that the first tests available on Vivalytic are our industry-leading multiplex panels for respiratory and sexually transmitted infections. This Randox-Bosch partnership enables quick, accurate diagnosis, improved patient care and the effective stewardship of critical medicines.”

“We are enthusiastic about having gained Randox as the first partner on our platform with two initial panels available from the start. It´s the beginning of jointly expanding the Vivalytic test portfolio for our clients,” said Marc Meier, General Manager of Bosch Healthcare Solutions. “In this partnership the core competencies of Bosch in automation, miniaturization, and networking are complemented by Randox’s expertise in developing and commercializing innovative diagnostic solutions.”

E-mail Print
FaceBook Twitter Google+ Linked in

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmaceutical companies and veterinary clinics, including clinical chemistry and immunoassay analysers, high quality reagents, and quality control material.
Platinum member
More info

More articles about Randox Laboratories

28 Oct 2020
Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership
The game-changing partnership between Randox Laboratories (Crumlin, UK) and Bosch Healthcare (Waiblingen, Germany) continues to alter the testing landscape and capabilities of both laboratory and non-laboratory settings for rapidly detecting COVID-19.
Read More

Additional news

27 Jun 2022
Robot-Assisted Surgical Devices Market Driven by Increased Demand for Patient-Specific Surgeries
Given the growing incidence of lifestyle diseases and demand for affordable healthcare, effective surgery using robotic devices can result in a decline in treatment costs and drive the growth of the global robot-assisted surgical devices (RASD) market.
Read More
24 Jun 2022
Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests
Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction of customary closing conditions.
Read More
23 Jun 2022
Hospital Microbiology Testing Market Driven by Increasing Prevalence of Chronic Diseases
Rising medical expenditure as well as the presence of well-established modern healthcare infrastructure in various developed as well as developing regions is fueling the growth of the global hospital microbiology testing market.
Read More
22 Jun 2022
Global Minimally Invasive Surgery (MIS) Market to Surpass USD 325 Billion by 2031
The global MIS market is projected to surpass USD 325 billion by 2031, driven by growing patient awareness of the advantages of MIS over open surgeries, continuous innovation in surgical robots, and constant advancements in other MIS-associated technologies during the 2022-2031 forecast period.
Read More
21 Jun 2022
Medix Biochemica Acquires IVD Raw Materials Producer Bioresource Technology
Medix Biochemica (Espoo, Finland) has acquired 100% of the shares of Bioresource Technology (BRT, Weston, FL, USA) to broaden its base matrix capabilities and further strengthen its local presence in the US market.
Read More
21 Jun 2022
Global Bedside Testing Market to Witness Promising Prospects in Critical Care
Point-of-care or point-of-use diagnostics, also known as bedside testing, has gained increased prominence in analytical testing over the past few years as it provides clinically relevant information without the need for a dedicated laboratory.
Read More
20 Jun 2022
Global Sepsis Diagnostics Market Driven by Rising Hospital-Acquired Illnesses
The global sepsis diagnostics market is expected to grow at a CAGR of 8.3% during the period 2022-2028 to reach almost USD 0.88 billion by 2028, driven by a rise in the number of hospital-acquired illnesses and the rapidly growing molecular diagnostics market, although the high cost of automated diagnostic instruments could hamper market growth.
Read More
14 Jun 2022
BD Partners with Mayo Clinic Platform for Access to World's Largest Collection of Clinical Data
Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) has entered into a collaboration with Mayo Clinic Platform (Rochester, MN, USA) to access de-identified patient data from Mayo Clinic Platform_Discover.
Read More
14 Jun 2022
Quidel Partners with Global Lyme Alliance, Leads in Lyme Disease Testing
Quidel Corporation (San Diego, CA, USA) is joining forces with Global Lyme Alliance (Stamford, CT, USA) to heighten public awareness around Lyme disease during Lyme Disease Awareness Month (in May) and beyond.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions